{"id":"NCT00853606","sponsor":"VIVUS LLC","briefTitle":"Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction","officialTitle":"An Open-Label, Long-Term Evaluation of the Safety and Efficacy of Avanafil in Men With Erectile Dysfunction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2010-04","completion":"2010-04","firstPosted":"2009-03-02","resultsPosted":"2012-06-28","lastUpdate":"2012-08-17"},"enrollment":712,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Erectile Dysfunction"],"interventions":[{"type":"DRUG","name":"avanafil","otherNames":["TA-1790","Stendra"]}],"arms":[{"label":"avanafil","type":"EXPERIMENTAL"}],"summary":"This open-label study is being conducted to evaluate the long-term safety, tolerability, and efficacy of avanafil in men with mild to severe erectile dysfunction. Approximately 400 subjects will be enrolled and treated with avanafil for up to 52 weeks.","primaryOutcome":{"measure":"Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse.","timeFrame":"Baseline, 52 weeks","effectByArm":[{"arm":"Avanafil","deltaMin":54.75,"sd":35.915}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":2},"locations":{"siteCount":40,"countries":["United States"]},"refs":{"pmids":["23521325"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":712},"commonTop":["headache","flushing","nasopharyngitis","nasal congestion"]}}